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ABSTRACT Avermectins are powerful endectocides with an established potential to
reduce the incidence of vector-borne diseases. Here, we show that several avermec-
tins inhibit the hepatic stage of Plasmodium infection in vitro. Notably, ivermectin
potently inhibits liver infection in vivo by impairing parasite development inside
hepatocytes. This impairment has a clear impact on the ensuing blood stage para-
sitemia, reducing disease severity and enhancing host survival. Ivermectin has been
proposed as a tool to control malaria transmission because of its effects on the mos-
quito vector. Our study extends the effect of ivermectin to the early stages of mam-
malian host infection and supports the inclusion of this multipurpose drug in ma-
laria control strategies.
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Despite recent achievements, malaria remains a formidable public health problem,primarily affecting children in the poorest regions of the world. Plasmodium
parasites, the causative agents of malaria, are transmitted to humans as sporozoites
(spz) through the bite of infected Anopheles mosquitoes. Injected spz travel to the liver
and initiate an asymptomatic, yet obligatory, replication and differentiation phase (1).
This intrahepatic developmental process culminates in the release of thousands of
merozoites into the bloodstream, where they cyclically infect red blood cells, causing
disease symptoms and originating gametocytes that warrant the progress of infection
in the mosquito vector. Historically, successful malaria control interventions have
combined effective vector control strategies, capable of interrupting transmission, and
strong antiparasitic drugs that prevent disease and death. However, current tools are
precarious and calls have recently been made for the development of new drug
formulations or the repurposing of old drug formulations as valuable interventions to
help control malaria infection (2).
Avermectins are a family of macrocyclic lactones that includes compounds present-
ing not only a best-in-class antiparasitic activity but also a strong insecticidal effect (3).
Their impact on vector populations led to the suggestion of a potential role for
avermectins in reducing the incidence of vector-borne disease (4). In particular, iver-
mectin, a semisynthetic member of the avermectin family, revolutionized the treatment
of nematode and arthropod parasites in animals and is commonly used to treat
neglected tropical diseases such as onchocerciasis, lymphatic filariasis, and strongy-
loidiasis (5–7). More recently, ivermectin has emerged as a potential tool for malaria
control (4, 8–10), given its insecticidal effect (11–16), its ability to inhibit Plasmodium
falciparum sporogony (17), its inhibitory effect on the blood stages of Plasmodium
berghei (in vivo) and P. falciparum (in vitro) (18), and its ability to disrupt parasite
transmission (19–21). However, no reports on the effect of avermectins on Plasmodium
liver stages exist so far.
Here, we investigated the effects of avermectins on the liver stages of P. berghei
parasites and showed that ivermectin is remarkably active against this stage of the
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malaria parasite’s life cycle. These results provide further support for the potential of
ivermectin, a drug that is already employed in mass drug administration (MDA) in
regions where malaria is endemic and has an established impact on malaria transmis-
sion, as a multipurpose, multistage tool for malaria control.
RESULTS
Avermectins inhibit Plasmodium infection of human hepatoma cells in vitro.
The effect of emamectin, eprinomectin, and ivermectin on the in vitro infection of Huh7
cells by luciferase-expressing P. berghei parasites was measured by using a biolumi-
nescence assay (22). Our data show that all three avermectins tested are active against
Plasmodium liver stages, with 50% inhibitory concentrations (IC50s) of 2 M, equiv-
alent to 2.6, 2.2, and 2.1 g/ml for emamectin, eprinomectin, and ivermectin, respec-
tively (see Fig. S1 in the supplemental material). Treatment at different periods of
infection further indicated that these avermectins act mainly during the parasite’s
intrahepatic development phase, as the strongest effect occurs when the drugs are
added to the cells after completion of the invasion process (Fig. 1A). The invasion and
development phenotypes in the presence of the compounds were further analyzed by
FIG 1 Avermectins inhibit the development of Plasmodium hepatic stages in vitro. (A) Huh7 cells were
infected with luciferase-expressing P. berghei spz and treated with the IC90s of avermectins or with
equivalent amounts of dimethyl sulfoxide (DMSO; control) for the times indicated. Total parasite loads
(bioluminescence) and cell viability were assessed at 48 hpi. (B) Parasite invasion was quantified by flow
cytometry at 2 hpi with GFP-expressing P. berghei spz by determining the percentage of GFP cells. (C)
Hepatic parasite numbers at 48 hpi were quantified by immunofluorescence microcopy. (D, E) Parasite
development at 48 hpi was assessed by flow cytometry (D) and immunofluorescence microscopy (E) by
determining the fluorescence intensity of GFP cells and the area of developing parasites, respectively. (F)
The effect of avermectin treatment on PVM structure, somatic integrity, and schizogony was analyzed by
immunofluorescence microcopy employing antibodies against PbUIS4 (a PVM protein, in green), PbHSP70
(a heat shock protein that localizes to the parasite soma, in red), and the nuclear stain Hoechst (in blue).
Representative confocal images show P. berghei hepatic forms treated with the IC90s of different avermec-
tins or with dimethyl sulfoxide (control) from 2 to 48 hpi. Scale bars, 10 m. Plots represent the mean values
of at least three independent experiments with error bars indicating the standard deviations. The Mann-
Whitney test was employed to assess the statistical significance of differences (*, P  0.05).
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a flow cytometry-based approach (23). These data suggested an effect of eprinomectin
on the ability of the parasites to invade Huh7 cells, which was not observed with either
emamectin or ivermectin (Fig. 1B). Furthermore, quantification of the infected cells at
48 h postinfection (hpi) by either flow cytometry (Fig. 1B) or immunofluorescence
microscopy (Fig. 1C) showed no significant changes in the overall number of intracel-
lular Plasmodium parasites. On the contrary, avermectins strongly impair the parasite’s
ability to develop inside cells. Measurement of green fluorescent protein (GFP) intensity
in cells at 48 hpi, a correlate of parasite development, showed that avermectins inhibit
parasite replication, particularly when present between 2 and 24 h of infection (Fig. 1D).
This effect was confirmed by immunofluorescence microscopy analysis of infected cells
incubated with drugs at their IC90s throughout the 48-h infection period (Fig. 1E and F).
Nonetheless, treatment with avermectins does not disrupt parasitophorous vacuole
membrane (PVM) formation and does not affect the localization of the PVM-resident
protein, upregulated in spz 4, PbUIS4 (Fig. 1F) or of the circumsporozoite protein PbCSP
(see Fig. S2). Avermectin treatment does significantly impact somatic integrity and
schizogony, as the parasite’s DNA appears to be strongly condensed (Fig. 1F; see Fig.
S2). Overall, our results show that avermectins inhibit Plasmodium hepatic infection by
impairing the parasite’s ability to develop inside cells.
Ivermectin decreases the liver Plasmodium load in vivo. We further evaluated the
effect of avermectins in the context of a physiologically relevant Plasmodium liver
infection. Emamectin, eprinomectin, and ivermectin were administered to mice by oral
gavage on a three-dose administration schedule of 10-mg/kg solutions in soybean oil
(Fig. 2A). Mice were infected by mosquito bite injection of P. berghei spz 24 h after the
first drug administration, and the parasite load was assessed 44 to 46 h after parasite
administration. Our data show that 80% inhibition of liver infection in vivo is observed
upon treatment with 10 mg/kg ivermectin but not upon treatment with emamectin or
eprinomectin, an effect comparable to that obtained with an equivalent administration
of primaquine, the only licensed liver stage antiplasmodial drug (24) (Fig. 2B and C). It
should be noted that upon administration of 10 mg/kg ivermectin, some mice dis-
played behavioral signs of neurotoxicity. However, equally of note, strong impairment
of infection was also observed when lower doses of ivermectin (1, 5, and 8 mg/kg) were
administered following a similar regimen (see Fig. S3). Since avermectins have a strong
insecticidal effect on Anopheles mosquitoes (8), we examined whether the observed
effect on liver infection resulted from deficient mosquito-to-mammal parasite trans-
mission because of an alteration of the mosquito feeding behavior on drug-treated
mice. To investigate this, we initially inspected the mosquitoes’ feeding pattern on
drug- and vehicle-treated mice. Our data show that mosquito feeding behavior was not
altered by the presence of avermectins in circulation (see Fig. S4A), whereas, not
surprisingly, they strongly affected mosquito survival after feeding (see Fig. S4B). We
then questioned whether the amount of Plasmodium spz deposited into the skin would
be influenced by the circulating avermectins. The bioluminescence signal correspond-
ing to the parasites deposited into mouse skin was measured immediately after a
mosquito blood meal, revealing no significant differences between groups of mice (see
Fig. S4C and D). Overall, our data show that although the presence of avermectins in
circulation has no effect on the feeding behavior of Plasmodium-infected mosquitoes or
on spz deposition into mammalian host skin, ivermectin displays a marked effect on P.
berghei liver infection in vivo.
Ivermectin impairs parasite development in the liver and impacts host sur-
vival. To investigate the basis of the observed impairment of in vivo liver infection by
ivermectin, infected mouse livers were analyzed by immunofluorescence microscopy at
46 hpi. Our analysis showed that ivermectin-treated mice had fewer (Fig. 3A) and
significantly less developed (Fig. 3B and C) liver parasites than those of vehicle-treated
control mice. We then investigated whether the ivermectin-dependent reduction of
liver infection would impact the appearance of parasites in the blood and the ensuing
pathology. To this end, infection was allowed to proceed past the liver stage and blood
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stage parasitemia, disease symptoms, and mouse survival were monitored for 10 days
following parasite administration. Our results show that the impairment of liver parasite
development caused by ivermectin treatment affects the onset of blood parasitemia
(Fig. 3D) and, most importantly, has a clear impact on host survival, with 80% of the
treated mice surviving for 10 days, compared with all of the control mice dying with
symptoms of experimental cerebral malaria (ECM) within the same period (Fig. 3E).
FIG 2 Ivermectin decreases liver infection in vivo. (A) Schematic illustration of the in vivo experimental
setup. The arrows indicate when each avermectin was orally administered at 10 mg/kg. Vehicle- or
primaquine (10 mg/kg)-treated mice were used as controls. P. berghei spz were delivered by the bites of
5 to 7 mosquitoes. (B) Representative bioluminescence images of mouse livers at 48 hpi. (C) Liver parasite
infection loads in mice treated with the various compounds, relative to those in DMSO-treated controls.
Dots represent the radiance intensity of individual liver areas relative to the average radiance of all
DMSO-treated mice. The total number of mice (n) in each data set and the number of independent
biological replicate experiments (N) performed are indicated. The statistical significance of differences
from the DMSO-treated mice was calculated by employing the nonparametric Mann-Whitney test. P
values are indicated above each data set (***, P  0.001). Horizontal dark lines indicate the relative mean
liver parasite infection load, whereas the vertical bars and shaded area represent the standard deviation
of the mean. PQ, primaquine; Emam, emamectin; Epri, eprinomectin; Iver, ivermectin.
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Overall, these results show that ivermectin significantly abrogates liver infection by
impairing parasite development and survival in hepatic cells, which impacts the ensu-
ing blood parasite burden and contributes to enhanced host survival.
DISCUSSION
Avermectins are widely used for protection against a wide spectrum of parasitic
diseases. Various avermectins have been synthesized, with different antiparasitic effi-
cacies and pharmacokinetic profiles, including one, ivermectin, that is safe and well
tolerated in humans. Several studies have shown that ivermectin has a strong insecti-
cidal effect that could be explored as a potential tool against malaria transmission (9).
Besides, inhibitory effects of ivermectin against the sporogonic and blood stages of the
Plasmodium life cycle have been described, highlighting its potential as a multistage
malaria intervention strategy (17, 18).
The effect of avermectins on the liver stage of Plasmodium infection had hitherto
not been assessed. Nevertheless, the relatively low numbers of parasites that infect
hepatocytes, coupled with the obligatory and asymptomatic natures of this phase of
infection, make the liver a privileged target for prophylactic intervention (1, 25).
Moreover, the existence of Plasmodium species capable of forming hypnozoites, par-
FIG 3 Ivermectin treatment inhibits parasite development in hepatocytes and improves the outcome of
disease. (A) Parasite density per square millimeter of liver section following treatment with ivermectin,
primaquine, or the vehicle at 48 hpi. (B) Effect of treatment on the parasite area as a correlate of parasite
development at 48 hpi. Darker colors indicate parasite areas of 250 m2, intermediate shading
indicates areas between 250 and 750 m2, and lighter bars indicate parasite areas of 750 m2. (C)
Representative confocal microscopy images of liver parasites in treated and control mice. Green, PbUIS4
labeling showing the PVM; blue, Hoechst nuclear staining. Scale bars,10 m. (D) Assessment of the
prepatency period and blood parasitemia by bioluminescence assays at various time points after spz
administration and drug treatment as in Fig. 2A. The mean bioluminescence  the standard errors of the
pooled data of 15 mice from three biological replicate experiments is presented for each of the time
points analyzed. A statistical analysis of the mean parasitemia observed across time was performed by
using the nonparametric Friedman test, which indicated a significant difference, with a P value of 0.05
(*). (E) Mouse survival following spz administration and drug treatment as in Fig. 2A. The mean
percentage of live animals  the standard errors of the pooled data of 15 mice from three biological
replicate experiments is shown for daily records, starting at the second day after spz administration and
drug treatment and up to 10 days pi. The Mantel-Cox (log rank) test was employed to compare survival
curves, indicating statistically significant differences, with a P value of 0.001 (***) for both the
primaquine- and ivermectin-treated groups compared to the DMSO-treated controls.
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asite forms that remain dormant in the liver for long periods of time, demands effective
ways of clearing hepatic parasites before they can cause disease relapses. We originally
described a potential inhibition of Plasmodium hepatic infection by ivermectin as part
of the results obtained in a drug screen targeting Plasmodium liver stages (26). We now
demonstrate that ivermectin is the only compound of the avermectin family assessed
in the present study that is active against Plasmodium liver stages in vivo. We confirm
that ivermectin treatment strongly decreases parasite load in vivo, to a degree that is
comparable to that of primaquine. Ivermectin strongly inhibits parasite development in
the liver, which has a strong impact on the ensuing pathology and host survival,
decreasing the magnitude of the blood stage infection and protecting from cerebral
disease.
The exact mechanism of action of primaquine remains elusive but may involve
impairment of the parasites’ mitochondrial metabolism or the production of highly
reactive metabolites that generate intracellular oxidative potentials (reviewed in refer-
ences 24 and 27). Azithromycin, another drug with demonstrated activity against P.
berghei liver stages, is proposed to act by blocking apicoplast development, leading to
impaired parasite maturation (28). However, the molecular mechanism of ivermectin
inhibition of Plasmodium liver stages is currently unknown. In the mosquito, the
primary target of ivermectin is the invertebrate glutamate-gated chloride channel
(GluCl) (29). Ivermectin has also been shown to kill the parasite’s blood stages by
blocking the nuclear import of the P. falciparum signal recognition particle (SRP), a
family of six polypeptides involved in protein targeting to the endoplasmic reticulum
(18). Recently, ivermectin was shown to be a ligand for farnesoid X receptor (NR1H4)
(30), whose activation has a critical role in regulating the homeostasis of glucose, a
molecule that plays a pivotal role during hepatic Plasmodium infection (31).
A recent modeling study has shown that adding ivermectin to mass treatment
strategies with artemether-lumefantrine can help reduce/interrupt malaria transmission
(32), and efforts are being made to develop a suitable slow-release formulation (33).
Our results now show that besides its recognized effect on mosquitoes, ivermectin
inhibits Plasmodium development inside hepatic cells, the obligatory initial stage of the
malaria parasite’s infection of its mammalian host. Thus, our study lends further support
to the use of ivermectin as a tool for malaria control and warrants further investigation
of the impact of ivermectin MDA on this devastating disease.
MATERIALS AND METHODS
Mice, parasites, and reagents. Male C57BL/6 mice 6 to 8 weeks old were purchased from Charles
River and housed in facilities of the Instituto de Medicina Molecular (iMM), Lisbon. Experimental
procedures were performed in accordance with the Federation of European Laboratory Animal Science
Associations guidelines and iMM regulations. In experiments involving blood stage infections, mice were
euthanized at the first behavioral signs of onset of ECM, and this was considered the experimental
endpoint. When no ECM was observed, mice were euthanized at day 10 postinfection (pi), the end of the
time frame for the development of this phenotype. A GFP/luciferase-expressing P. berghei ANKA
transgenic parasite line (676m1cl1) was used in all experiments. Mosquitoes were bred at the insectary
facility of the iMM. All of the chemicals used were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Quantification of in vitro parasite infection. For IC50 and IC90 determinations, compounds were
added to the cells prior to spz addition and incubated for 48 h. In all other experiments, compounds were
used at their IC90s and incubated for the times indicated. The infection load of human hepatoma Huh7
cells was determined by bioluminescence measurements as previously described (22). Invasion and
intracellular parasite development were assessed by determining the percentage of GFP cells at 2 hpi
and GFP intensity at 48 hpi, respectively, as previously described (23). The Mann-Whitney test was
employed to assess the statistical significance of differences (P  0.05; GraphPad Prism v5).
Immunofluorescence microscopy analysis of in vitro and in vivo hepatic infections. For in vitro
studies, cells seeded onto coverslips were fixed at 48 hpi with 4% (vol/vol) paraformaldehyde for 10 min
at room temperature (RT), permeabilized/blocked with 0.1% (vol/vol) Triton X-100 –1% (wt/vol) bovine
serum albumin in 1 phosphate-buffered saline (PBS) for 30 min at RT, and incubated with anti-Hsp70
and anti-UIS4 antibodies for 1 h at RT, followed by adequate secondary antibodies and Hoechst 33342
for 1 h at RT. For in vivo studies, fixed sections of livers collected at 48 hpi (intravenous [i.v.] adminis-
tration of 30,000 spz) were similarly stained. Images were acquired with a Zeiss 510 Meta confocal
microscope and a Zeiss Axiovert 200 M microscope and then processed with the ImageJ software.
Quantification of in vivo hepatic infection and blood stage parasitemia. In vivo parasite loads in
mice were determined by real-time in vivo imaging 30 min and 44 to 46 h after 15 min of exposure to
Mendes et al. Antimicrobial Agents and Chemotherapy











































five to seven infected Anopheles stephensi mosquitoes with the in vivo IVIS Lumina Imaging System as
previously described (22). Additionally, real-time PCR analysis of specific P. berghei 18S rRNA and mouse
hypoxanthine guanine phosphoribosyl transferase (HPRT)-encoding housekeeping genes in infected
livers collected at 44 to 46 hpi was performed as previously described (34). The nonparametric
Mann-Whitney test was applied to assess the statistical significance of differences between liver parasite
loads (P  0.001; GraphPad Prism v5). Blood stage parasitemia following the i.v. injection of 5,000 spz was
assessed by collecting 5 l of tail blood between days 2 and 6 pi in 50 l of lysis buffer. Bioluminescence
was then measured following the addition of 50 l of D-luciferin dissolved in firefly luciferase assay buffer
to 30 l of lysate with an Infinite M200 multiplate reader (Tecan). The nonparametric Friedman test was
applied to assess the statistical significance of differences between the mean parasitemias observed
across time in mice subjected to the different drug treatments (P  0.05; GraphPad Prism v5).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
AAC.02005-16.
TEXT S1, PDF file, 0.8 MB.
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